117 related articles for article (PubMed ID: 17929671)
21. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
[TBL] [Abstract][Full Text] [Related]
22. [Mouse monoclonal antibodies recognizing melanoma-associated ganglioside antigens].
Hirabayashi Y; Matsumoto M; Taniguchi M
Seikagaku; 1985 Oct; 57(10):1385-90. PubMed ID: 2418135
[No Abstract] [Full Text] [Related]
23. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
[No Abstract] [Full Text] [Related]
24. Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen.
Zheng XJ; Yang F; Zheng M; Huo CX; Zhang Y; Ye XS
Org Biomol Chem; 2015 Jun; 13(22):6399-406. PubMed ID: 25982227
[TBL] [Abstract][Full Text] [Related]
25. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.
Ragupathi G; Koide F; Livingston PO; Cho YS; Endo A; Wan Q; Spassova MK; Keding SJ; Allen J; Ouerfelli O; Wilson RM; Danishefsky SJ
J Am Chem Soc; 2006 Mar; 128(8):2715-25. PubMed ID: 16492059
[TBL] [Abstract][Full Text] [Related]
26. Chemical and chemoenzymatic synthesis of S-linked ganglioside analogues and their protein conjugates for use as immunogens.
Rich JR; Wakarchuk WW; Bundle DR
Chemistry; 2006 Jan; 12(3):845-58. PubMed ID: 16196067
[TBL] [Abstract][Full Text] [Related]
27. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.
Qiu L; Gong X; Wang Q; Li J; Hu H; Wu Q; Zhang J; Guo Z
Cancer Immunol Immunother; 2012 Nov; 61(11):2045-54. PubMed ID: 22539085
[TBL] [Abstract][Full Text] [Related]
28. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.
Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067
[TBL] [Abstract][Full Text] [Related]
29. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
30. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
31. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.
Yamamoto S; Yamamoto T; Saxton RE; Hoon DS; Irie RF
J Natl Cancer Inst; 1990 Nov; 82(22):1757-60. PubMed ID: 1700134
[TBL] [Abstract][Full Text] [Related]
32. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
33. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells.
Zou W; Borrelli S; Gilbert M; Liu T; Pon RA; Jennings HJ
J Biol Chem; 2004 Jun; 279(24):25390-9. PubMed ID: 15047693
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
35. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins.
Baruffaldi F; Kelcher AH; Laudenbach M; Gradinati V; Limkar A; Roslawski M; Birnbaum A; Lees A; Hassler C; Runyon S; Pravetoni M
Mol Pharm; 2018 Nov; 15(11):4947-4962. PubMed ID: 30240216
[TBL] [Abstract][Full Text] [Related]
37. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
[TBL] [Abstract][Full Text] [Related]
39. An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature.
Huijbers EJM; van Beijnum JR; Lê CT; Langman S; Nowak-Sliwinska P; Mayo KH; Griffioen AW
Vaccine; 2018 May; 36(21):3054-3060. PubMed ID: 29655625
[TBL] [Abstract][Full Text] [Related]
40. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies.
Zhang J; Terreni M; Liu F; Sollogoub M; Zhang Y
Biomed Pharmacother; 2024 Jul; 176():116824. PubMed ID: 38820973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
